natgillin/translations-raw huggingface dataset:
INTEGRILIN solution for injection must be used in conjunction with INTEGRILIN solution for infusion.
INTEGRILIN otopina za injekcije mora se upotrebljavati zajedno s INTEGRILIN otopinom za infuziju.
Integrilin solution for injection: 10 ml vial, pack of one vial.
Integrilin otopina za injekcije: bočica s 10 ml, kutija s jednom bočicom.
INTEGRILIN-treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding.
Nema pokazatelja da su bolesnici liječeni INTEGRILINOM, a imali su protrombinsko vrijeme (PV) > 14,5 sekundi i istodobno primali varfarin, bili izloženi većem riziku od krvarenja.
INTELENCE (200 mg b.i.d.), evaluated in combination with other antiretroviral medicinal products in a study of 15 pregnant women during the second and third trimesters of pregnancy and postpartum, demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum, and less so for unbound etravirine exposure (see section 5.2).
U ispitivanju s 15 trudnica, procijenjen je INTELENCE (200 mg dva puta na dan) u kombinaciji s drugim antiretrovirusnim lijekovima tijekom drugog i trećeg tromjesečja trudnoće i postpartalnog razdoblja, pri čemu se pokazalo da je izloženost ukupnom etravirinu općenito veća tijekom trudnoće u odnosu na postpartalno razdoblje, što se manje pokazalo za izloženost nevezanom etravirinu (vidjeti dio 5.2).
INTELENCE (see
INTELENCE (vidjeti
INTELENCE and
INTELENCE i
INTELENCE and raltegravir
INTELENCE i raltegravir
INTELENCE can be
INTELENCE se može
INTELENCE can be
INTELENCE se može dati u
INTELENCE can be
R(-) metadon
INTELENCE can be used
može se koristiti bez
Intelence does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Intelence ne liječi infekciju HIV-a ili SIDA-e, no može odgoditi oštećenje imunosnog sustava te razvoj infekcija i bolesti povezanih sa SIDA -om.
Intelence etravirine
Intelence etravirin
Intelence has also been studied in one main study involving 101 children aged between six and 17 years old who were infected with HIV and were already taking anti-HIV medicines.
Intelence je također ispitan u jednom glavnom ispitivanju koje je obuhvatilo 101 dijete u dobi između šest i 17 godina koji su bili zaraženi HIV-om, a uzimali su već lijekove protiv HIV-a.
Intelence has been studied in two main studies in adults, involving a total of 1,203 HIV-infected adults who had been taking anti-HIV therapy that was not working any longer and who had few or no treatment options remaining.
Intelence je ispitivan u dva glavna ispitivanja u odraslih osoba, obuhvaćajući ukupno 1.203 odrasla bolesnika zaražena HIV-om koji su uzimali terapiju protiv HIV-a koja više nije bila učinkovita, a kojima je preostalo samo nekoliko drugih mogućnosti za liječenje ili nemaju više mogućnosti za liječenje.
INTELENCE has no or negligible influence on the ability to drive and use machines.
INTELENCE ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
INTELENCE has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is therefore not recommended (see sections 4.2 and 4.4).
INTELENCE nije ispitan kod bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C) i stoga se ne preporučuje (vidjeti dio 4.2 i 4.4).
INTELENCE has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and its use is therefore not recommended in this group of patients (see sections 4.2 and 5.2).
INTELENCE nije ispitivan kod bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C) stoga se njegova primjena ne preporučuje u toj skupini bolesnika (vidjeti dijelove 4.2 i 5.2).
Intelence is a medicine that contains the active substance etravirine.
Intelence je lijek koji sadrži djelatnu tvar etravirin.
INTELENCE is expected to increase nelfinavir plasma concentrations.
Očekuje se da će INTELENCE povećati koncentracije nelfinavira u plazmi.
INTELENCE is expected to increase plasma concentrations of warfarin.
Očekuje se da INTELENCE povećava koncentracije varfarina u plazmi.
Intelence is only used in patients who have been treated for their HIV infection before.
Intelence se koristi samo u bolesnika koji su prethodno liječeni za infekciju HIV-a.
Intelence is used to treat adults and children from six years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Intelence se koristi za liječenje odraslih i djece u dobi od šest godina koji su inficirani virusom humane imunodeficijencije tip 1 (HIV-1), virusom koji uzrokuje sindrom stečene imunodeficijencije (SIDA).
INTELENCE may result in lower plasma
INTELENCE i telaprevira
Intelence must be used together with other anti-HIV medicines that include a ‘boosted protease inhibitor’.
Intelence se mora koristiti zajedno s drugim lijekovima protiv HIV-a koji uključuju „pojačani inhibitor proteaze”.
INTELENCE should be used in combination with a boosted protease inhibitor (PI).
INTELENCE treba primjenjivati zajedno s pojačanim inhibitorom proteaze (IP).
INTELENCE should only be used with dolutegravir when co-administered with
jedino kada se istodobno primjenjuju atazanavir/ritonavir,
INTELENCE should optimally be combined with other antiretrovirals that exhibit activity against the patient’s virus (see section 5.1).
INTELENCE je optimalno koristiti u kombinaciji s drugim antiretrovirusnim lijekovima koji pokazuju aktivnost protiv virusa u bolesnika (vidjeti dio 5.1).
INTELENCE tablets should be stored in the original bottle.
Tablete INTELENCE treba čuvati u originalnoj bočici.
Intelence was more effective than placebo at reducing viral load in adults.
Intelence je bio djelotvorniji od placeba u smanjivanju virusnog opterećenja u odraslih osoba.
Intelence was originally given ‘conditional approval’ because there was more evidence to come about the medicine, in particular regarding its use in combination with protease inhibitors other than darunavir.
Za lijek Intelence prvotno je izdano „uvjetno odobrenje” zato što se mora dostaviti još dokaza o lijeku, a posebice u svezi s njegovom primjenom u kombinaciji s drugim inhibitorima proteaza osim darunavira.
INTELENCE with a boosted
INTELENCE.
INTELENCE.
jednokratna doza
INTELENCE.
s INTELENCE-om.
Intense lack of energy
intenzivan manjak energije
Intense pain on injection.
Intenzivna bol prilikom ubrizgavanja.
Intensification of therapy with insulin, a component of Xultophy, with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long- term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Intenziviranje terapije inzulinom, sastavnicom lijeka Xultophy, s naglim poboljšanjem regulacije glikemije može biti povezano s privremenim pogoršanjem dijabetičke retinopatije, dok dugoročno poboljšanje regulacije glikemije smanjuje rizik napredovanja dijabetičke retinopatije.
Intensified monitoring of adverse reactions is recommended in patients with impaired hepatic function as exposure is expected to be increased in this population, in particular in patients with severe hepatic impairment.
U pacijenata s oštećenom funkcijom jetre preporučuje se pojačani nadzor zbog nuspojava budući da se u ovoj populaciji očekuje povećana izloženost, posebice u pacijenata s teškim oštećenjem funkcije jetre.
Intensity of the adverse reactions is graded according to NCI CTC version 3.0 (grade ≥3 = G≥3).
Intenzitet nuspojava stupnjevan je prema verziji 3.0 Općih kriterija toksičnosti Nacionalnog instituta za rak (NCI CTC) (stupanj ≥ 3 = G ≥ 3).
intensive care unit (ICU) or similar
odjelu gdje je osigurano pomno kliničko
Intent to Treat
Populacija planirana za liječenje
Intent to Treat
Populacija planirana za liječenje (ITT)
Intent to Treat Populationb
ITT Populacijab
Intent to Treat Populationb
Populacija uključena u ispitivanjeb
Intent-to-treat
Populacija planirana za liječenje
Intent-to-Treat Analysis Set+
Komplet analize namjere liječenja+
Intent-to-treat Population
Intent-to-treat populacija
Intent-To-Treat Population
Populacija s namjerom liječenja (ITT)
Intent-to-treat population using last observation in study prior to glycaemic rescue therapy. p < 0.001 compared to placebo.
„Intent to treat“ populacija (planirana za liječenje) koristeći posljednje zapažanje u ispitivanju. p<0,001 u usporedbi s placebom.
Intent-to-treat populations of each study are shown below:
Intent-to-treat) u pojedinom ispitivanju prikazani su ispod:
Intention-to-treat (ITT) data set.
Skup podataka za populaciju koja se namjerava liječiti (ITT).
Inter-ethnic differences
Međuetničke razlike
Inter-individual variability (CV) of riociguat exposure (AUC) across all doses is approximately 60%.
Interindividualna varijabilnost (CV) izloženosti riocigvatu (AUC) kod svih doza je približno 60%.
Inter-individual variability in peak and overall exposure is approximately 20-30%
Interindividualna varijabilnost vršne i ukupne izloženosti približno je 20-30
Inter-rater agreement using Fleiss’ kappa values ranged from 0.75 to 0.85.
Slaganje među ocjeniteljima primjenom Fleiss kappa vrijednosti kretalo se u rasponu od 0,75 do 0,85.
Interaction
Antacidi
Interaction
ANTIARITMICI
Interaction
Dizopiramid
Interaction
Dojenje
Interaction
Fenobarbital
Interaction
ispitivanju:
Interaction
Simvastatin ↑↑
Interaction
STEROIDI
Interaction affecting the use of ONIVYDE
Interakcije koje utječu na primjenu lijeka ONIVYDE
Interaction Geometric mean change (%)
Interakcija Geometrijska srednja vrijednost promjene (%)
Interaction not studied
interakcija nije ispitivana
Interaction not studied
Interakcija nije ispitivana.
Interaction not studied
Nema studija interakcije.
Interaction not studied with
Interakcija nije ispitana s
Interaction not studied with
Interakcija nije ispitana sa Stribildom.
Interaction not studied with any of the components of Eviplera.
Interakcija nije ispitana ni s jednom komponentom lijeka Eviplera.
Interaction not studied with any of the components of Odefsey.
Interakcija nije ispitana ni s jednom komponentom lijeka Odefsey.
Interaction not studied with efavirenz, emtricitabine, or tenofovir disoproxil fumarate.
Nije ispitana interakcija s efavirenzom, emtricitabinom niti tenofovirdizoproksil fumaratom.
Interaction not studied with elvitegravir.
organske anione (OATP) u
Interaction not studied with elvitegravir.
plazmi očekivano se ne
Interaction not studied with tenofovir alafenamide.
Interakcija nije ispitana s tenofovir alafenamidom.
Interaction not studied.
interakcija.
Interaction not studied.
Istodobna primjena
Interaction not studied.
U tromjesečnom ispitivanju interakcije
Interaction of P-gp substrates
Interakcija sa supstratima P-glikoproteina
Interaction of vemurafenib with drug transport systems
Interakcija između vemurafeniba i sustava prijenosa lijeka
Interaction on medicinal products metabolised by CYP 2D6: beta blockers, antidepressants
Interakcija s lijekovima koji se metaboliziraju pomoću CYP2D6: beta-blokatori, antidepresivi
Interaction on medicinal products metabolized by CYP 3A4
Interakcija s lijekovima koji se metaboliziraju pomoću CYP3A4
Interaction on metformin (OCT1 and OCT2 substrate)
Interakcija s metforminom (supstratom OCT1 i OCT2)
Interaction on omeprazole (CYP 2C19 substrate)
Interakcija s omeprazolom (supstratom CYP2C19)
Interaction on theophylline (CYP 1A2 substrate)
Interakcija s teofilinom (supstratom CYP1A2)
Interaction on warfarin and losartan (CYP 2C9 substrates)
Interakcija s varfarinom i losartanom (supstratima CYP2C9)
Interaction only studied with sofosbuvir
Interakcija ispitana samo sa sofosbuvirom
Interaction only studied with velpatasvir
Interakcija ispitana samo s velpatasvirom
Interaction only studied with velpatasvir
Interakcija ispitana samo s velpatasvirom.
interaction should be taken into
lopinavir/ritonavir tablete/efavirenz
Interaction studies conducted in healthy subjects, using mainly a single dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
Ispitivanja interakcija provedena sa zdravim ispitanicima, uglavnom s primjenom jedne doze, ukazuju na to da metformin, pioglitazon, sitagliptin, glimepirid, vogliboz, hidroklorotiazid, bumetanid, valsartan i simvastatin ne mijenjaju farmakokinetiku dapagliflozina.
Interaction studies conducted in healthy subjects, using mainly a single-dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
Ispitivanja interakcija provedena sa zdravim ispitanicima, uglavnom primjenom jedne doze, ukazuju na to da pioglitazon, sitagliptin, glimepirid, vogliboz, hidroklorotiazid, bumetanid, valsartan i simvastatin ne mijenjaju farmakokinetiku dapagliflozina.
Interaction studies for Cubicin were performed with aztreonam, tobramycin, warfarin and probenecid.
Provedena su ispitivanja interakcije Cubicina s aztreonamom, tobramicinom, varfarinom i probenecidom.
Interaction studies have been performed only in adults.
Ispitivanja interakcija provedena su samo u odraslih.
Interaction studies have not been conducted in patients on dialysis.
Nisu provedena ispitivanja interakcija u bolesnika na dijalizi.
Interaction studies have only been performed in adults
Ispitivanja interakcija provedena su samo u odraslih.
Interaction studies have only been performed in adults.
Ispitivanja interakcija lijekova provodila su se samo kod odraslih osoba
Interaction studies have only been performed in adults.
Ispitivanja interakcija provedena su samo na odraslima.
Interaction studies have only been performed in adults.
Ispitivanja interakcija provođena su samo u odraslih bolesnika.
Interaction studies have only been performed in adults.
Ispitivanja interakcija provođena su samo u odraslih bolesnika..
Interaction studies have only been performed in adults.
Ispitivanja interakcija s drugim lijekovima provedena su samo na odraslim osobama.
Interaction studies have only been performed in adults.
Ispitivanja interakcija su jedino provedena kod odraslih osoba.
Interaction studies have only been performed in adults.
Ispitivanja interakcija su provedena samo na odraslima.
Interaction studies have only been performed in adults.
Ispitivanja interakcije provedena su samo na odraslim osobama.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Ispitivanja interakcija pokazala su da pioglitazon nema važan učinak niti na farmakokinetiku niti na farmakodinamiku digoksina, varfarina, fenprokumona i metformina.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Ispitivanja interakcija pokazala su da pioglitazon nema važne učinke na farmakokinetiku i farmakodinamiku digoksina, varfarina, fenprokumona i metformina.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Ispitivanja interakcija pokazala su da pioglitazon nema važne učinke niti na farmakokinetiku niti na farmakodinamiku digoksina, varfarina, fenprokumona i metformina.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin.
Ispitivanja interakcija pokazala su da pioglitazon nema značajnog učinka na farmakokinetiku ni farmakodinamiku digoksina, varfarina, fenprokumona i metformina.
Interaction studies of mirabegron with metoprolol and with metformin used mirabegron immediate-release (IR) 160 mg.
Ispitivanja interakcije mirabegrona s metoprololom i metforminom koristila su mirabegron s neposrednim oslobaĎanjem (engl. immediate release – IR) od 160 mg.
Interaction studies with a 3A4 inhibitor have not been carried out in vivo.
Ispitivanja interakcije s 3A4 inhibitorom nisu bila provođena in vivo.
Interaction studies with exenatide have only been performed in adults.
Ispitivanja interakcija s eksenatidom provedena su samo u odraslih.
Interaction studies with these agents have only been performed in adults.
Ispitivanja interakcija s tim lijekovima provedena su samo u odraslih.
Interaction study performed only with ritonavir
provedeno samo s
Interaction study with Lopinavir/ritonavir + rosuvastatin:
Ispitivanje interakcije s lopinavirom/ritonavirom + rosuvastatinom: AUC rosuvastatina  2,08 puta
interaction with bone void fillers
interakcijama s punilima za šupljine u kostima
Interaction with CYP3A4 inhibitors
Interakcije s inhibitorima CYP3A4
Interaction with didanosine: Co-administration of Atripla and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Interakcija s didanozinom: Ne preporučuje se istovremena primjena Atriple i didanozina jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Interaction with didanosine: Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Interakcija s didanozinom: Ne preporučuje se istovremena primjena tenofovirdizoproksilfumarata i didanozina, jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Interaction with Grapefruit juice
Interakcije sa sokom od grejpa
Interaction with indinavir/ritonavir not studied
Nije ispitana interakcija s
Interaction with indinavir/ritonavir not studied
Nije ispitivana interakcija s indinavirom/ritonavirom.
Interaction with indinavir/ritonavir not studied Morphine levels may be decreased due to induction of glucuronidation by coadministered ritonavir.
Nije ispitivana interakcija s indinavirom/ritonavirom.
Interaction with inducers of both CYP3A4 and P-gp
Interakcija s induktorima CYP3A4 i P-gp-a
Interaction with Invirase/ritonavir not
Interakcija s lijekovima Invirase/ritonavir nije ispitivana.
Interaction with Invirase/ritonavir not
Nije dovršeno niti jedno ispitivanje farmakokinetičkih interakcija.
Interaction with Invirase/ritonavir not studied.
Interakcija s lijekovima Invirase/ritonavir nije ispitivana.
Interaction with Invirase/ritonavir not studied.
U bolesnika koji se
Interaction with Invirase/ritonavir not studied.-
Interakcija s lijekovima Invirase/ritonavir nije ispitivana.
Interaction with other medicaments and other forms of interaction
Interakcije s drugim lijekovima i drugi oblici interakcija
Interaction with other medicaments:
Interakcije s drugim proizvodima
Interaction with other medicinal products
Interakcija s drugim lijekovima
Interaction with other medicinal products affecting haemostasis
Interakcije s drugim lijekovima koji utječu na hemostazu
Interaction with other medicinal products and other forms of interaction
Interakcija s drugim lijekovima i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcija s drugim lijekovima i drugi oblici interakcije
Interaction with other medicinal products and other forms of interaction
Interakcija s drugim lijekovima i ostali oblici interakcije
Interaction with other medicinal products and other forms of interaction
Interakcija s drugim veterinarsko medicinskim proizvodima i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcija s drugim veterinarsko-medicinskim proizvodima i drugi oblici interakcije
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim lije kovima i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim lijekovim i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim lijekovima i ostali obici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim lijekovima i ostali oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim lijekovima ili drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija:
Interaction with other medicinal products and other forms of interaction
Interakcije s drugim VMP i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Interakcije s s drugim lijekovima i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction
Međusobno djelovanje s drugim medicinskim proizvodima i drugi oblici međusobnog djelovanja
Interaction with other medicinal products and other forms of interaction A number of medicinal products are known to interact with glucose metabolism.
Interakcije s drugim lijekovima i drugi oblici interakcija Poznato je da niz lijekova stupa u interakciju s metabolizmom glukoze.
Interaction with other medicinal products and other forms of interaction Interaction studies have only been performed in adults.
Interakcije s drugim lijekovima i drugi oblici interakcija Ispitivanja interakcija provedena su samo u odraslih osoba.
Interaction with other medicinal products and other forms of interaction Interaction studies have only been performed in adults.
Interakcije s drugim lijekovima i drugi oblici interakcija Ispitivanja interakcija provedena su samo u odraslih.
Interaction with other medicinal products and other forms of interaction Intravenous Anaesthetics:
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija Intravenski anestetici:
Interaction with other medicinal products and other forms of interaction:
Interakcija sa drugim medicinskim proizvodima i druge vrste interakcije:
Interaction with other medicinal products and other forms of interaction:
Interakcija sa drugim medicinskim proizvodima i ostali oblici interakcije:_
Interaction with other medicinal products and other forms of interaction:
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija.
Interaction with other medicinal products and other forms of interaction:
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija;
Interaction with other medicinal products and other forms of interaction:
Interakcije s drugim veterinarsko-medicinskim proizvodima i drugi oblici interakcija:
Interaction with other medicinal products and other forms of interaction:
Interakcije s drugim VMP i drugi oblici interakcija
Interaction with other medicinal products and other forms of interaction: For subcutaneous route:
Interakcija sa ostalim veterinarsko medicinskim preparatima i ostale vrste interakcija:
Interaction with other medicinal products and other forms of interaction: Inform your veterinary surgeon if your dog is using other medicines.
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija: Obavijestite svog veterinara ako pas dobiva druge lijekove.
Interaction with other medicinal products and other forms of interaction: None known.
Interakcije s drugim medicinskim proizvodima ili drugi oblik interakcije Nisu poznate.
Interaction with other products and other forms of interaction:
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija:
Interaction with other veterinary medicinal products and other forms of interaction Intravenous Anaesthetics:
Interakcije s drugim veterinarsko-medicinskim proizvodima i drugi oblici interakcija Intravenski anestetici:
Interaction with P-gp inducers
Interakcije s induktorima P-gp